Comparing Gabapentin with Clonazepam for Residual Sleeping Problems following Antidepressant Therapy in Patients with Major Depressive Disorder: A Randomized Clinical Trial

Mowla, Arash; Ahmadzadeh, Laaya; Jahromi, Leila Razeghian; Dastgheib, Seyed Ali

doi:10.1007/s40261-015-0304-8

Cited by 7 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, gabapentin did not differ from placebo on tests of daytime drowsiness and performance. [33] Off-label clinical studies also reported beneficial effects of gabapentin on sleep,[34–39] as well as on anxiety[40] and mood. [41–49] A medication that decreases drinking in animal models of alcohol dependence[50] and improves symptoms of negative affect and sleep disturbance in clinical samples is of significant interest as a potential treatment for decreasing drinking relapse risk in the protracted withdrawal phase of alcohol dependence.…”

Section: Gabapentin: An Old Anticonvulsant With a New Potentialmentioning

confidence: 99%

Gabapentin for the treatment of alcohol use disorder

Mason

Quello

Shadan

2017

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Alcohol misuse is the fifth leading risk factor for premature death and disability worldwide. Fewer than 10% of afflicted Americans receive pharmacological treatment for alcohol use disorder. Gabapentin is a calcium channel GABAergic modulator that is widely used for pain. Studies showing reduced drinking and decreased craving and alcohol-related disturbances in sleep and affect in the months following alcohol cessation suggest therapeutic potential for alcohol use disorder. Areas covered: Human laboratory and clinical studies assessing gabapentin for alcohol use disorder are reviewed. Data were obtained by searching for English peer-reviewed articles on PubMed, reference lists of identified articles, and trials registered on clinicaltrials.gov. Additionally, the mechanism of action of gabapentin specific to alcohol use disorder, and studies of gabapentin for alcohol withdrawal and non-alcohol substance use disorders are summarized. Expert opinion: Alcohol use disorder represents a challenge and large, unmet medical need. Evidence from single-site studies lend support to the safety and efficacy of gabapentin as a novel treatment for alcohol use disorder, with unique benefits for alcohol-related insomnia and negative affect, relative to available treatments. Proprietary gabapentin delivery systems may open a path to pivotal trials and registration of gabapentin as a novel treatment for alcohol use disorder.

show abstract

Section: Gabapentin: An Old Anticonvulsant With a New Potentialmentioning

confidence: 99%

Gabapentin for the treatment of alcohol use disorder

Mason

Quello

Shadan

2017

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

“…In a randomized, controlled, double-blind study (44), 63 MDD patients with residual sleep disturbances (PSQI >5 or ISI > 8) were randomized to receive either gabapentin in doses (100-600 mg/d) or clonazepam (0.5-2 mg/d). After 4 weeks both groups improved in both aforementioned scales, without showing any statistical difference between each drug, which proves gabapentin may be equally efficacious as clonazepam in treating residual sleep disturbances.…”

Section: Studies On Residual Insomnia Treatment Psychopharmacologymentioning

confidence: 99%

Residual insomnia in major depressive disorder: a systematic review

Kwaśny¹,

Włodarczyk²,

Dywel³

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

IntroductionThe ultimate goal in major depressive disorder (MDD) treatment is recovery. A proportion of MDD patients with formal remission experience persistent difficulties, which impair their daily functioning. Residual insomnia is one of the most common residual symptoms. Patients with residual insomnia experience relapse significantly earlier and have a poor prognosis. Little is known about possible ways of treatment and what subtype of insomnia is mostly reported.MethodsA systematic literature review was carried out in PubMed and Web of Science to synthesize the current status of knowledge about effective treatment methods and insomnia subtypes in residual insomnia in MDD.ResultsA few non-pharmacological treatment methods e.g., Cognitive Behavioral Therapy for Insomnia (CBT-I), Mindfulness-Based Cognitive Therapy (MBCT), behavioral activation (BA) and pharmacological methods (gabapentin, clonazepam) have proven to mitigate residual insomnia. Cognitive Behavioral Therapy for Depression (CBT-D) ameliorates insomnia complaints to a limited extent. Mid-nocturnal insomnia is the most common residual insomnia subtype in MDD patients.ConclusionResidual insomnia is a very common complaint and most often appears as mid-nocturnal insomnia. Scarce data points out the benefits from pharmacotherapy, psychotherapy, and BA. More research is needed.

show abstract

“…Gabapentin is an anticonvulsant that is widely used to treat insomnia [Mowla et al, ], neuropathic pain [Kremer et al, ], drug and alcohol addiction [Mason et al, ], anxiety [Lavigne et al, ], borderline personality disorder [Peris et al, ], menopausal conditions [Yadav and Volkar, ], vertigo [Straube, ], prurititis [Straube, ] and migraine [Perloff et al, ]. Gabapentin is a GABA analog but is not an agonist at either the GABA A or GABA B receptors and does not interact with GABA uptake transporters [Offord and Isom, ].…”

Section: Introductionmentioning

confidence: 99%

Synergistic Interaction of a Gabapentin‐ Mangiferin Combination in Formalin‐Induced Secondary Mechanical Allodynia and Hyperalgesia in Rats Is Mediated by Activation of NO‐Cyclic GMP‐ATP‐Sensitive K⁺ Channel Pathway

Godínez‐Chaparro

Quiñonez-Bastidas

Rojas-Hernández

et al. 2017

Drug Development Research

View full text Add to dashboard Cite

Preclinical Research Gabapentin is an anticonvulsant used to treat neuropathic pain. Mangiferin is an antioxidant that has antinociceptive and antiallodynic effects in inflammatory and neuropathic pain models. The purpose of this study was to determine the interaction between mangiferin and gabapentin in the development and maintenance of formalin-induced secondary allodynia and hyperalgesia in rats. Gabapentin, mangiferin, or their fixed-dose ratio combination were administrated peripherally. Isobolographic analyses was used to define the nature of the interaction of antiallodynic and/or antihyperalgesic effects of the two compounds. Theoretical ED values for the combination were 74.31 µg/paw and 95.20 µg/paw for pre- and post-treatment, respectively. These values were higher than the experimental ED values, 29.45 µg/paw and 37.73 µg/paw respectively, indicating a synergistic interaction in formalin-induced secondary allodynia and hyperalgesia. The antiallodynic and antihyperalgesic effect induced by the gabapentin/mangiferin combination was blocked by administration of L-NAME, the soluble guanylyl cyclase inhibitor, ODQ and glibenclamide. These data suggest that the gabapentin- mangiferin combination produces a synergistic interaction at the peripheral level. Moreover, the antiallodynic and hyperalgesic effect induced by the combination is mediated via the activation of an NO-cyclic GMP-ATP-sensitive K channel pathway. Drug Dev Res 78 : 390-402, 2017. © 2017 Wiley Periodicals, Inc.

show abstract

Comparing Gabapentin with Clonazepam for Residual Sleeping Problems following Antidepressant Therapy in Patients with Major Depressive Disorder: A Randomized Clinical Trial

Abstract: This study revealed that gabapentin is comparable to clonazepam for treating sleeping problems associated with major depression.

Cited by 7 publications

References 31 publications

Gabapentin for the treatment of alcohol use disorder

Gabapentin for the treatment of alcohol use disorder

Residual insomnia in major depressive disorder: a systematic review

Synergistic Interaction of a Gabapentin‐ Mangiferin Combination in Formalin‐Induced Secondary Mechanical Allodynia and Hyperalgesia in Rats Is Mediated by Activation of NO‐Cyclic GMP‐ATP‐Sensitive K⁺ Channel Pathway

Contact Info

Product

Resources

About

Comparing Gabapentin with Clonazepam for Residual Sleeping Problems following Antidepressant Therapy in Patients with Major Depressive Disorder: A Randomized Clinical Trial

Abstract: This study revealed that gabapentin is comparable to clonazepam for treating sleeping problems associated with major depression.

Cited by 7 publications

References 31 publications

Gabapentin for the treatment of alcohol use disorder

Gabapentin for the treatment of alcohol use disorder

Residual insomnia in major depressive disorder: a systematic review

Synergistic Interaction of a Gabapentin‐ Mangiferin Combination in Formalin‐Induced Secondary Mechanical Allodynia and Hyperalgesia in Rats Is Mediated by Activation of NO‐Cyclic GMP‐ATP‐Sensitive K+ Channel Pathway

Contact Info

Product

Resources

About

Synergistic Interaction of a Gabapentin‐ Mangiferin Combination in Formalin‐Induced Secondary Mechanical Allodynia and Hyperalgesia in Rats Is Mediated by Activation of NO‐Cyclic GMP‐ATP‐Sensitive K⁺ Channel Pathway